Patrick Trucchio analyst HC WAINWRIGHT

Currently out of the existing stock ratings of Patrick Trucchio, 491 are a BUY (98.59%), 4 are a SELL (0.8%), 3 are a HOLD (0.6%).

Patrick Trucchio

Work Performance Price Targets & Ratings Chart

Analyst Patrick Trucchio, currently employed at HC WAINWRIGHT, carries an average stock price target met ratio of 20.34% that have a potential upside of 48.64% achieved within 184 days. Previously, Patrick Trucchio worked at BERENBERG.

Patrick Trucchio’s has documented 841 price targets and ratings displayed on 42 stocks. The coverage is on Healthcare, Financial Services sectors.

Most recent stock forecast was given on ANRO, Alto Neuroscience at 11-May-2026.

Wall Street Analyst Patrick Trucchio

Analyst best performing recommendations are on ANRO (ALTO NEUROSCIENCE).
The best stock recommendation documented was for QURE (UNIQURE NV) at 9/8/2025. The price target of $70 was fulfilled within 50 days with a profit of $52.57 (301.61%) receiving and performance score of 60.32.

Average potential price target upside

ALLK Allakos ALNY Alnylam Pharmaceuticals ATAI ATAI Life Sciences BV CMPS Compass Pathways Plc FLXN Flexion Therapeutics MNK Mallinckrodt plc CYBN Cybin  FSTX FStar Therapeutics FTRP Field Trip Health Ltd MNMD Mind Medicine  VIR Vir Biotechnology ALT Altimmune ARWR Arrowhead Pharmaceuticals ARNA Arena Pharmaceuticals BNTC Benitec Biopharma Ltd ADR DMTTF Small Pharma FIXX Homology Medicines FRLN Freeline Therapeutics Holdings Plc GHRS GH Research PLC IMCR Immunocore Holdings Ltd LBPH Longboard Pharmaceuticals MIST Milestone Pharmaceuticals MSSTF Mindset Pharma PRGO Perrigo Company PLC SLN Silence Therapeutics PLC DTIL Precision BioSciences GOSS Gossamer Bio IVVD Invivyd ONCY Oncolytics Biotech QURE Uniqure NV SGMO Sangamo Therapeutics BEAM Beam Therapeutics  HRMY Harmony Biosciences Holdings VYGR Voyager Therapeutics ENTA Enanta Pharmaceuticals SUPN Supernus Pharmaceuticals ALL The Allstate ANRO Alto Neuroscience ASMB Assembly Biosciences FR First Industrial Realty Trust NRXP NRX Pharmaceuticals PHVS Pharvaris BV

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

$3

$1.79 (147.93%)

$3

1 years 9 months 11 days ago
(26-Sep-2024)

0/4 (0%)

$2.42 (417.24%)

Hold

$7

2 years 17 days ago
(20-Jun-2024)

1/3 (33.33%)

$0.45 (6.87%)

57

Sell

$1

$-0.21 (-17.36%)

$1.5

2 years 5 months 20 days ago
(17-Jan-2024)

6/6 (100%)

$-0.02 (-1.96%)

278

Buy

2 years 6 months 19 days ago
(18-Dec-2023)

1/1 (100%)

$32.69 (83.16%)

358

Buy

$9

$7.79 (643.80%)

3 years 1 months 26 days ago
(11-May-2023)

2/4 (50%)

$4.84 (116.35%)

178

Show more analysts

Please expand the browser size to see the chart

Which stock is Patrick Trucchio is most bullish on?

Potential upside of $197.22 has been obtained for ALNY (ALNYLAM PHARMACEUTICALS)

Which stock is Patrick Trucchio is most reserved on?

Potential downside of -$0 has been obtained for CMPS (COMPASS PATHWAYS PLC)

What Year was the first public recommendation made by Patrick Trucchio?

On 2018

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?